Tango Therapeutics
Quarterly Financials
| Values in thousands | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 |
|---|---|---|---|---|
Revenue | $11,607 | $19,875 | $6,471 | $5,431 |
Gross Profit | 11,607 | 19,243 | 5,846 | 4,814 |
EBITDA | -32,256 | -28,920 | -41,630 | -34,396 |
EBIT | -32,878 | -29,552 | -42,255 | -35,013 |
Net Income | -29,167 | -25,551 | -37,914 | -30,763 |
Net Change In Cash | 11,607 | 19,875 | 6,471 | 5,431 |
Free Cash Flow | -33,505 | -23,927 | -38,052 | -27,693 |
Cash | 53,148 | 51,566 | 61,163 | 66,385 |
Basic Shares | 108,507 | 108,314 | 108,171 | 97,223 |
Annual Financials
| Values in thousands | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 |
|---|---|---|---|---|
Revenue | $36,527 | $24,860 | $37,042 | $7,656 |
Gross Profit | -78,671 | 24,860 | 37,042 | 6,031 |
EBITDA | -111,758 | -109,463 | -57,293 | -51,482 |
EBIT | -114,173 | -111,071 | -58,190 | -53,107 |
Net Income | -101,744 | -108,176 | -58,235 | -51,864 |
Net Change In Cash | 36,527 | 24,860 | 37,042 | 7,656 |
Cost of Revenue | -81,066 | 114,364 | ||
Free Cash Flow | -119,508 | -116,772 | -61,364 | 68,968 |
Cash | 66,385 | 59,968 | 142,745 | 28,381 |
Basic Shares | 94,572 | 87,820 | 62,108 | 31,932 |
Earnings Calls
| Quarter | EPS |
|---|---|
2024-09-30 | -$0.27 |
2024-06-30 | -$0.24 |
2024-03-31 | -$0.35 |
2023-12-31 | -$0.32 |
